Analyst Price Target is $2.00
▲ +475.37% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Kazia Therapeutics in the last 3 months. The average price target is $2.00, with a high forecast of $2.00 and a low forecast of $2.00. The average price target represents a 475.37% upside from the last price of $0.35.
Current Consensus is
The current consensus among 1 investment analysts is to buy stock in Kazia Therapeutics. This Buy consensus rating has held steady for over two years.
Kazia Therapeutics Limited operates as a biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma, diffuse intrinsic pontine glioma/advanced solid tumors, atypical teratoid rhabdoid tumor, brain metastases, triple negative breast cancer, and primary central nervous system lymphoma. It is also developing EVT801, a small molecule targeted therapeutic vascular endothelial growth factor receptor 3 inhibitor. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. The company was incorporated in 1994 and is based in Sydney, Australia.